NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

Phase 1

Phase 2

NT219 & PembrolizumabNT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor:

University of Colorado, Denver

Code:

NCT06919666

Conditions

Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NT219

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-18. This information was provided to ClinicalTrials.gov by University of Colorado, Denver on 2025-10-10.